Form 4: Akero Therapeutics CEO Sells $1.5 Million in Stock Under Pre-Arranged Trading Plan

Akero Therapeutics, Inc. President and CEO Andrew Cheng sold 30,000 shares of common stock for approximately $1.5 million through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Andrew Cheng, President and CEO of Akero Therapeutics, Inc., and a Director, executed two sales of common stock on July 10, 2025.
• The first transaction involved the sale of 14,686 shares at a weighted-average price of $50.57 per share, with prices ranging from $50.03 to $50.98.
• The second transaction involved the sale of 15,314 shares at a weighted-average price of $51.732 per share, with prices ranging from $51.06 to $52.05.
• In total, 30,000 shares of common stock were sold for an aggregate value of approximately $1,549,860.
• Following these transactions, Andrew Cheng beneficially owns 520,757 shares of Akero Therapeutics common stock.
• All reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by Andrew Cheng.

Sentiment

Score: 5

Explanation: The transaction was a pre-planned sale under a Rule 10b5-1 plan, which typically indicates a scheduled liquidity event rather than a reaction to new company-specific information, thus having a neutral sentiment impact.

Positives

• The stock sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the transactions were scheduled in advance and not based on new, non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, though the impact is mitigated by the Rule 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical industries as executives manage personal liquidity and diversification. These pre-scheduled sales are generally viewed as less indicative of management's immediate outlook on the company's prospects compared to unscheduled sales.

Stakeholder Impact

• Shareholders: The sale by a key executive, while pre-planned, may lead to minor market scrutiny, but the impact is generally limited due to the 10b5-1 plan mitigating concerns about new negative information.

Key Dates

Keywords

Akero Therapeutics, AKRO, Andrew Cheng, CEO, Insider Sale, Stock Transaction, Form 4, 10b5-1 Plan, Common Stock